SAFETY OF ROXADUSTAT VERSUS ERYTHROPOIESIS-STIMULATING AGENTS FOR TREATMENT OF ANEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE INCIDENT TO OR NOT RECEIVING DIALYSIS: POOLED ANALYSIS OF FOUR PHASE 3 STUDIES - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Nephrology Dialysis Transplantation Année : 2022

SAFETY OF ROXADUSTAT VERSUS ERYTHROPOIESIS-STIMULATING AGENTS FOR TREATMENT OF ANEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE INCIDENT TO OR NOT RECEIVING DIALYSIS: POOLED ANALYSIS OF FOUR PHASE 3 STUDIES

(1) , (2) , , (3, 4) , , , ,
1
2
3
4
Fichier non déposé

Dates et versions

hal-03732942 , version 1 (21-07-2022)

Identifiants

  • HAL Id : hal-03732942 , version 1

Citer

Jonathan Barratt, Frank Dellanna, Jose Portoles, Gabriel Choukroun, Luca de Nicola, et al.. SAFETY OF ROXADUSTAT VERSUS ERYTHROPOIESIS-STIMULATING AGENTS FOR TREATMENT OF ANEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE INCIDENT TO OR NOT RECEIVING DIALYSIS: POOLED ANALYSIS OF FOUR PHASE 3 STUDIES. Nephrology Dialysis Transplantation, 2022, 37 (3), pp.I387-I388. ⟨hal-03732942⟩

Collections

U-PICARDIE MP3CV
19 Consultations
0 Téléchargements

Partager

Gmail Facebook Twitter LinkedIn More